[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

June 2019 | 121 pages | ID: CDA0684C1AFEN
La Merie Publishing

US$ 900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.

At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).

The report highlights the use of bispecific antibody technology for generation of
  • T-Cell Redirecting Bispecific Antibodies
  • Bispecific Natural Killer (NK) Cell Redirecting Antibodies
  • Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies
  • Bispecific Immuno-Oncology Antibodies
  • Bispecific Tumor Associated Antigen (TAA)/Growth Factor Targeted Antibodies
  • Bispecific Antibodies for Non-Cancer Indications
research and development of bispecific therapeutic antibodies in cancer and non-cancer indications. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.
1) T-CELL REDIRECTING BISPECIFIC ANTIBODIES

Targeting BCMA
Targeting CD20
Targeting CD19
Targeting CD33
Targeting CD123
argeting PSMA
Targeting Her2
Targeting Mesothelin
Targeting CD38
Targeting EGF-R
Targeting DLL3
Targeting Various Other Cancer Surface Antigens
Targeting Not Disclosed Tumor Associated Antigens
Targeting (Intracellular) peptide/MHC Antigens
Novel Bispecific T-Cell Redirecting Antibody Constructs
Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases

2) BISPECIFIC NATURAL KILLER (NK) CELL REDIRECTING ANTIBODIES

3) BISPECIFIC T-CELL ENGAGING, CONDITIONAL COSTIMULATORY ANTIBODIES

Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
Bispecific, Dual Costimulatory Antibodies

4) BISPECIFIC IMMUNO-ONCOLOGY ANTIBODIES

Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
Bispecific Checkpoint Inhibitor & Costimulator Antibodies
Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
Bispecific, Not Specified Immuno-Oncology Antibodies

5) BISPECIFIC TUMOR ASSOCIATED ANTIGEN (TAA) / GROWTH FACTOR TARGETED ANTIBODIES –

Bispecific Her2-Targeted Antibodies
Bispecific VEGF-Targeted Antibodies
Other Bispecific TAA-Targeted Antibodies

6) BISPECIFIC ANTIBODIES FOR NON-CANCER INDICATIONS

Bispecific Inflammatory & Autoimmune Disease Antibodies
Bispecific Cardiometabolic Antibodies
Bispecific Ophthalmic Disease Antibodies
Bispecific Neurologic Disease Antibodies
Bispecific Infectious Disease Antibodies
Bispecific Antibodies For Targeted Delivery


More Publications